| Title: |
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC) : a randomised controlled trial |
| Authors: |
Harris, Victoria; Holmes, Jane; Gbinigie-Thompson, Oghenekome; Rahman, Najib M; Richards, Duncan B; Hayward, Gail; Dorward, Jienchi; Lowe, David M; Standing, Joseph F; Breuer, Judith; Khoo, Saye; Petrou, Stavros; Hood, Kerenza; Ahmed, Haroon; Carson-Stevens, Andrew; Nguyen-Van-Tam, Jonathan S; Patel, Mahendra G; Saville, Benjamin R; Francis, Nick; Thomas, Nicholas P B; Evans, Philip; Dobson, Melissa; Png, May Ee; Lown, Mark; Van Hecke, Oliver; Jani, Bhautesh D; Hart, Nigel D; Butler, Daniel; Cureton, Lucy; Patil, Meena; Andersson, Monique; Coates, Maria; Bateman, Clare; Davies, Jennifer C; Raymundo-Wood, Ivy; Ustianowski, Andrew; Yu, Ly-Mee; Hobbs, F D Richard; Little, Paul; Butler, Christopher C; Moftah, Areej; Goodman, Anna; Halifax, Rob; Turnbull, Chris; Sundaralingam, Anand; Agyeman, Akosua; Shah, Divya; Brown, Julianne; Thalasselis, Chris; Woodall, Maximillian N J; Yongblah, Francis; Howell, Aleksandra; Patel, Kavil; Hussain, Iqbal; Penfold, Ruth; Hutchinson, Simon; Poonian, Satveer; Imlach, Marie; Popoola, Olajide; Irving, Greg; Pora, Alexander; Jacobsen, Nicholas; Prasad, Vibhore; Kennard, James; Prasad, Rishabh; Khan, Umar; Razzaq, Omair; Knox, Kyle; Richardson, Scot; Krasucki, Christopher; Royal, Simon; Law, Tom; Safa, Afsana; Lee, Rem; Sehdev, Satash; Lester, Nicola; Sevenoaks, Tamsin; Lewis, David; Sheikh, Aadil; Lunn, James; Short, Vanessa; Mackintosh, Claire; Singh Sidhu, Baljinder; Mathukia, Mehul; Singh, Ivor; Moore, Patrick; Soni, Yusuf; Morton, Seb; Wilson, Pete; Murphy, Daniel; Wingfield, David; Nally, Rhiannon; Wong, Michael; Ndukauba, Chinonso; Wooding, Nick; Ogundapo, Olufunto; Woods, Sharon; Okeke, Henry; Yong, Joanna; Ahmed, Tanveer; Allcock, Damien; Atherton, George; Beltran-Martinez, Adrian; Benedict, Oluseye Emmanuel; Bird, Nigel; Brennan, Laura; Burns, Gerard; Butler, Mike; Cheng, Zelda; Danson, Ruth; De Kare-Silver, Nigel; Dhasmana, Devesh; Dickson, Jon; Engamba, Serge; Fisher, Stacey; Fox, Robin; Frost, Eve; Gaunt, Richard; Ghosh, Sarit; Gilkar, Ishtiaq; Granier, Steve; Packham, Alice; Dowsell, Sarah; Gulati, Radhika; Patel, Amit; PANORAMIC Trial Collaborative Grp, missing |
| Source: |
LANCET INFECTIOUS DISEASES ; ISSN: 1473-3099 ; ISSN: 1474-4457 |
| Publication Year: |
2025 |
| Collection: |
Ghent University Academic Bibliography |
| Subject Terms: |
Medicine and Health Sciences; RESPIRATORY-TRACT INFECTION; PRESCRIBING STRATEGIES |
| Description: |
Background No randomised controlled trials have yet reported on the effectiveness of molnupiravir on longer term outcomes for COVID-19. The PANORAMIC trial found molnupiravir reduced time to recovery in acute COVID-19 over 28 days. We aimed to report the effect of molnupiravir treatment for COVID-19 on wellbeing, severe and persistent symptoms, new infections, health care and social service use, medication use, and time off work at 3 months and 6 months post-randomisation. Methods This study is a follow-up to the main analysis, which was based on the first 28 days of follow-up and has been previously reported. For this multicentre, primary care, open-label, multi-arm, prospective randomised controlled trial conducted in the UK, participants were eligible if aged at least 50 years, or at least 18 years with a comorbidity, and unwell 5 days or less with confirmed COVID-19 in the community. Participants were randomly assigned to the usual care group or molnupiravir group plus usual care (800 mg twice a day for 5 days), which was stratified by age (= 50 years) and vaccination status (at least one dose: yes or no). The primary outcome was hospitalisation or death (or both) at 28 days; all longer term outcomes were considered to be secondary outcomes and included self-reported ratings of wellness (on a scale of 0-10), experiencing any symptom (fever, cough, shortness of breath, fatigue, muscle ache, nausea and vomiting, diarrhoea, loss of smell or taste, headache, dizziness, abdominal pain, and generally feeling unwell) rated as severe (moderately bad or major problem) or persistent, any health and social care use, health-related quality of life (measured by the EQ-5D-5L), time off work or school, new infections, and hospitalisation. Findings Between Dec 8, 2021, and April 27, 2022, 25 783 participants were randomly assigned to the molnupiravir plus usual care group (n=12 821) or usual care group (n=12 962). Long-term follow-up data were available for 23 008 (89.2%) of 25 784 participants with 11 ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://biblio.ugent.be/publication/01JHQ92FJRMCW3JV3XCEP1H887; https://biblio.ugent.be/publication/01JHQ92FJRMCW3JV3XCEP1H887/file/01JHQ93FRZFMACRQK4DWRYYQ3S |
| DOI: |
10.1016/s1473-3099(24)00431-6 |
| Availability: |
https://biblio.ugent.be/publication/01JHQ92FJRMCW3JV3XCEP1H887; https://hdl.handle.net/1854/LU-01JHQ92FJRMCW3JV3XCEP1H887; https://doi.org/10.1016/s1473-3099(24)00431-6; https://biblio.ugent.be/publication/01JHQ92FJRMCW3JV3XCEP1H887/file/01JHQ93FRZFMACRQK4DWRYYQ3S |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.46386B73 |
| Database: |
BASE |